Eur Rev Med Pharmacol Sci 2022; 26 (21): 7899-7904

DOI: 10.26355/eurrev_202211_30141

A new parameter predicting steroid response in idiopathic IgA nephropathy: a pilot study of pan-immune inflammation value

O. Tunca, E.D. Kazan

Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey. dronurtunca@hotmail.com


OBJECTIVE: In this pilot study, we aimed at investigating the predictive power of pan-immune inflammation value (PIV) on response rates at 6 months in idiopathic IgA nephropathy (IgAN) patients who started steroids.

PATIENTS AND METHODS: The study was conducted with patients diagnosed with idiopathic IgAN and treated with 3-6 months of conservative treatment and steroid therapy started because proteinuria was above 1 g/day. Patients with proteinuria lower than 0.3 g/day, no macroscopic hematuria, and no hematuria detected in 3 consecutive urinalyses for 6 months were considered to be patients in remission. PIV was calculated by [neutrophil count (103 µL)*platelet count (103 µL)*monocyte count (103 µL)]/lymphocyte count (103 µL)]. Patients were compared according to their remission status in terms of PIV.

RESULTS: The mean PIV was significantly higher in patients in the non-remission group than in patients in the remission group (1,869.2±1,781.9 to 574.1±364.5, respectively). The best cut-off for PIV was 752.6 to predict non-remission with a 75% sensitivity and 71.4% specificity.

CONCLUSIONS: Our study showed that PIV is a reliable marker for predicting steroid response at the 6th month in patients with idiopathic IgAN.

Free PDF Download

To cite this article

O. Tunca, E.D. Kazan
A new parameter predicting steroid response in idiopathic IgA nephropathy: a pilot study of pan-immune inflammation value

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 21
Pages: 7899-7904
DOI: 10.26355/eurrev_202211_30141